William Harvey Research Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK.
William Harvey Research Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK.
Drug Discov Today. 2016 Jan;21(1):172-179. doi: 10.1016/j.drudis.2015.10.014. Epub 2015 Oct 30.
Rheumatoid arthritis (RA) is a chronic, systemic, autoimmune disease that leads to excessive joint inflammation and is associated with significant morbidity and mortality. Although much is still to be learned about the aetiology RA, a growing body of evidence suggests that an altered vascular environment is an important aspect of its pathophysiology. In this context, RA shares many similarities with cancer, and it is expected that several angiogenic targets in cancer might be relevant to the treatment of RA. Here, we discuss how these targets can be combined with advances in drug development to generate the next generation of RA therapeutics.
类风湿关节炎（RA）是一种慢性、全身性、自身免疫性疾病，可导致过度的关节炎症，并与显著的发病率和死亡率相关。尽管 RA 的病因仍有许多有待了解，但越来越多的证据表明，改变的血管环境是其病理生理学的一个重要方面。在这种情况下，RA 与癌症有许多相似之处，预计癌症中的几个血管生成靶点可能与 RA 的治疗相关。在这里，我们讨论了如何将这些靶点与药物开发的进展相结合，以产生下一代 RA 治疗药物。
